Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0BI3N
|
|||
| Former ID |
DIB006023
|
|||
| Drug Name |
Cerdulatinib
|
|||
| Synonyms |
PRT-062070; Syk + JAK multikinase inhibitor (NHL/CLL/RA), Portola Pharmaceuticals
Click to Show/Hide
|
|||
| Indication | B-cell lymphoma [ICD-11: 2A86; ICD-10: C85.1; ICD-9: 202.8] | Phase 2 | [1] | |
| Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C85.9] | Phase 1/2 | [2] | ||
| Atopic dermatitis [ICD-11: EA80; ICD-10: L20; ICD-9: 691.8, 692.9] | Phase 1 | [3] | ||
| Vitiligo [ICD-11: ED63.0; ICD-10: L80-L99, L80; ICD-9: 709.01] | Phase 1 | [3] | ||
| Company |
Portola Pharmaceuticals Inc; portola pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H27N7O3S
|
|||
| Canonical SMILES |
CCS(=O)(=O)N1CCN(CC1)C2=CC=C(C=C2)NC3=NC=C(C(=N3)NC4CC4)C(=O)N
|
|||
| InChI |
1S/C20H27N7O3S/c1-2-31(29,30)27-11-9-26(10-12-27)16-7-5-15(6-8-16)24-20-22-13-17(18(21)28)19(25-20)23-14-3-4-14/h5-8,13-14H,2-4,9-12H2,1H3,(H2,21,28)(H2,22,23,24,25)
|
|||
| InChIKey |
BGLPECHZZQDNCD-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1198300-79-6
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of Portola. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Company report (Portola Pharmaceuticals) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.